A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome is a research paper published in Journal of Clinical Investigation (2023). On theSindex it has a DataRank of 1.2. It has been cited 42 times, with 35 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.564
From this paper's citation signal
Citation Network Contribution
0.626
From 25 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 35 citers.
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Grant: AI000615-28
NCI NIH HHS
Grant: 75N91019D00024
Intramural NIH HHS
Grant: Z01 AI000615
National Institutes of Health
Grant: 1ZIAAI000615-28
Molecular Analysis Of Leukocyte Activation By Chemoattractants
Fields of Study
MeSH Terms
Keywords